Semaglutide for prediabetes after gestational diabetes
Treatments studied
Part of Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies whether semaglutide can help women with prediabetes after past gestational diabetes return to better blood sugar levels and lower progression to diabetes. It is designed for women who are no longer breastfeeding and can use effective birth control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You previously had gestational diabetes during pregnancy (diagnosed by WHO criteria around 24–32 weeks, or earlier if early GDM)
- You were diagnosed with prediabetes within 6 weeks to 12 months after giving birth (by blood tests like fasting glucose, 2-hour OGTT, and/or HbA1c)
- You have stopped breastfeeding and you do not plan to get pregnant in the next year
- You can use effective contraception and you are not taking medicines that strongly affect blood sugar
- You can read and speak Dutch, French, or English, and you agree to the study in writing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a weekly injection (semaglutide) to see if it can help lower the risk of heart disease and type 2 diabetes in women who recently had gestational diabetes. The goal is to improve long-term health after pregnancy.
This Phase 4 study looks at how to help women with a recent history of gestational diabetes get their blood sugar back toward normal levels. It likely includes blood-sugar testing and a controlled diet period to see what works best.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This trial tests whether the medication semaglutide (often used for diabetes) can prevent the development of new diabetes after a kidney transplant. If you are in the early weeks after a transplant and have risk factors for diabetes, this study might help reduce your chances of developing diabetes later.
This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
Hear when a new Glucose Intolerance After a Recent History of Gestational Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.